CGON — Cg Oncology Inc · catalysts, narrative & risks

Snapshot (as of the 2026‑10‑16 close)

CG Oncology, Inc. (NASDAQ: CGON) is a late‑stage clinical biopharmaceutical company developing cretostimogene grenadenorepvec (CG0070) for non‑muscle‑invasive bladder cancer (NMIBC) in the United States [1][5][17]. As of 16 October 2026 the stock closed near $59.85 (down ~3.25% on the day), with a market capitalization of roughly $5.3 billion and a 52‑week range of $35.80–$80.97 [12][14][17]. Note that the unverified background file cited a ~$5.48B market cap and a next‑earnings date of 2026‑11‑09; the current data providers instead converge on a November 12–13 earnings window and a ~$5.3B cap, so the prior November 9 date should be treated as superseded [10][11].